MUC3A and neoplasm: For patient P01, standard approaches to tumor cell handling and neoantigen prediction yielded a limited set of three gene fusion–derived neoantigens (MUC3A-MUC3A epitopes, presented by various HLA types with differing stability and affinity) (Figure 2B,C).